MentionFox
Home › funding signals › Monocacy Therapeutics Inc.
Form D · on the record

Monocacy Therapeutics Inc. — $25K Form D filing, October 2026

Monocacy Therapeutics Inc. filed a Form D with the Securities and Exchange Commission on 2026-10-07.

Monocacy Therapeutics Inc. filed a Form D notice of an exempt securities offering with the SEC on October 7, 2026. The filing reports $25K sold. Its industry group is Biotechnology. It names Suman Vodnala (Executive Officer), Shashank Patel (Executive Officer, Director) (SEC Form D, October 7, 2026).

2 more Biotechnology raises in Maryland, October 2026 ↓

Sell to companies like Monocacy Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

Run the free check on Monocacy Therapeutics Inc. →

Monocacy Therapeutics Inc.

New Form D on file · 2026-10-07 · the record

$25K
raise on the record
D
filing
1
investors in
MARYLAND
based
Open the record →

What the record says

FilingForm D
Filed2026-10-07
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
Year formed2025
BasedMONROVIA, MARYLAND
CIK2137361
Accession0002137361-26-000006

Pitching, partnering or investing alongside them? See who really runs and owns Monocacy Therapeutics Inc.

Watch Monocacy Therapeutics Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind Monocacy Therapeutics Inc., from the filings we hold.

More raises like this

Biotechnology raises by companies based in Maryland, filed in October 2026, largest first.

What do you want to do with Monocacy Therapeutics Inc.?

Get the full cited report on Monocacy Therapeutics Inc.

What the filing shows about Monocacy Therapeutics Inc.

  • 1 investor had already put money in when it filed.
  • The filing names 2 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Monocacy Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

What the filing says

  • Offered: $25,000. Sold: $25,000. Left to sell: nothing, all of it is sold. (filing)
  • Investors: 1 had already invested. (filing)
  • Date of first sale: September 25, 2026. (filing)
  • Types of securities: Other: Simple Agreement for Future Equity (SAFE). (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Monocacy Therapeutics Inc. See pricing

Filing history · 6 filings on this registrant
Form D · 2026-05-27 · $114KForm D · 2026-08-28 · $150KForm D · 2026-08-28 · $125KForm D/A, amended · 2026-08-28 · $114KForm D · 2026-09-21 · $49Form D · 2026-10-07 · $25K · this page 2026-05-27 2026-10-07

A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.

Biotechnology · by week
This raise, $25K, filed week of Oct 5

Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $25K, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Monocacy Therapeutics Inc.?

What the filing shows about Monocacy Therapeutics Inc.

  • 1 investor had already put money in when it filed.
  • The filing names 2 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Monocacy Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Monocacy Therapeutics Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Monocacy Therapeutics Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for Monocacy Therapeutics Inc.. With no account yet, you sign up free and land on the result.

Share this page

Just raised? Share it.

Monocacy Therapeutics Inc.: Raised $25K, Form D filed 2026-10-07

Cite this page

Permanent URL: https://mentionfox.com/funding/monocacy-therapeutics-inc-form-d-000006
Last updated 2026-10-20
Primary record: SEC filing 1 · SEC filing 2
Monocacy Therapeutics Inc. raised $25K — SEC Form D filing, October 2026. MentionFox, 2026-10-20. https://mentionfox.com/funding/monocacy-therapeutics-inc-form-d-000006